GENEVA (Reuters) - Vaccine experts did not reach a conclusion about whether manufacturers should shift production to a H1N1 pandemic flu jab in their Thursday meeting organized by the World Health Organization, an official said.
Keiji Fukuda, acting WHO assistant director-general, said the industry and health officials participating in the teleconference reached “no big decisions, no pronouncements” about a change from seasonal flu vaccines.
“It is part of an ongoing discussion to look at what questions have to get addressed, how can you make those decisions, what evidence is there,” Fukuda told a news conference. “There will be additional meetings that continue.”
At least 20 companies worldwide make flu vaccines, including Sanofi-Aventis, Novartis, Baxter International, Australia’s CSL, and nasal spray maker MedImmune, now part of AstraZeneca.